Analysis of comorbid conditions in 1210 IPF patients from the EMPIRE registry
Bildiriler > Özet Bildiri · 2017
Yazarlar: Dragana M. Jovanovic, Nesrin MOĞULKOÇ BISHOP, Martina Sterclova, Beata Zolnowska, Vladimir Bartos, Martina Plackova, Veronika Muller, Ladislav Lacina, Robert Slivka, Martina Doubkova, Marina Roksandic Milenkovic, Radka Bittenglova, Imrich Jonner, Magdalena Martusewicz-Boros, Monika Zurkova, Ilona Binkova, Malgorzata Sobiecka, Richard Tyl, Marzena Trzaska-Sobczak, Pawel Sliwinski, Vladimira Lostakova, Sebastian Majewski, Pavlina Lisa, Katarzyna Lewandowska, Hana Suldova, Jasna Tekavec-Trkanjec, Amelia Szymanowska-Narloch, Lenka Siskova, Aniko Bohacs, Jan Plutinsky, Bohumil Matula, Stefan Toth, Frantisek Petrik, Margita Bucekova, Jana Psikalova, Miklos Zsiray, Jaroslav Lnenicka, Vladimir Rihak, Zsuzsanna Szalai, Zoltan Baliko, Stefan Lassan, Pavlina Musilova, Imre Lajko, Tomas Snizek, Jan Anton, Jiri Homolka, Peter Paluch, Robert Vysehradsky, Renata Kralova, Jan Kervitzer, Daniel Dolezal, Maria Szilasi, Jan Kus, Marta Hajkova, Michal Svoboda, Jana Strenkova, Martina Vasakova
Diffuse Parenchymal Lung Disease, İtalya, Uluslararası, Sözlü Sunum, Özet Bildiri, 2017-2017, Wos, cilt 50, ss OA1953-OA1953
DOI: 10.1183/1393003.congress-2017.oa1953
Özet
Most patients with IPF have comorbidities, which affect functional status, quality of life and survival. Our study aims are to analyze comorbidities in a series of 1210 IPF patients from the EMPIRE registry (European Multipartner IPF registry). Comorbidities were noted in 85.6% (1036pts), one in 23.5%, 2 in 23.0% and 3 or more in 53.5%. Median age at diagnosis was 67.2 years (range 50.0-82.2). Male to female ratio 68.8%:31.2%. The most frequent were cardiovascular diseases 68.1% (824pts), significantly more than in general population (GP) of similar age. Most common comorbidities were arterial hypertension 52.2% (632pts), diabetes 20.7% (251pts), coronary disease 20.1% (243pts), hyperlipidaemia 18.0% (218pts), GERD 14.0% (169pts), osteoporosis 11.6% (135pts), arrhythmias 8.8% (106pts), prostatic hypertrophy 10.3% of males (86pts), thyroid diseases 6.1% (74pts), pulmonary hypertension 5.3% (64pts), COPD 5.2% (63pts), depression 4.4% (53pts), asthma 3.3% (40pts), nephropathy 2.6% (31pts) etc. Sleep breathing disorder was registered in 1.0% (12pts), lung cancer 0.4% (5pts) and tuberculosis in 1.4% (17pts). The prevalence of arterial hypertension, coronary disease, arrhythmias, pulmonary hypertension, diabetes, osteoporosis, thyroid diseases and lung cancer was much higher than in European GP, as well as tuberculosis, while the prevalence of COPD, sleep breathing disorder, asthma, nephropathy, hyperlipidaemia, prostatic hypertrophy and depression was strikingly lower than in GP. Surprisingly the frequency of GERD was within the range of GP. Conclusion: Management of IPF requires a comprehensive approach, which includes the identification and treatment of comorbid conditions to optimize patient outcomes.